Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2020, Vol. 34 ›› Issue (6): 123-128.doi: 10.6040/j.issn.1673-3770.0.2020.031
Previous Articles Next Articles
ZHU ZhengruOveriew,ZHANG XiaobingGuidance
CLC Number:
| [1] 程雷, 钱俊俊, 田慧琴. 变应性鼻炎研究的若干进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021. CHENG Lei, QIAN Junjun, TIAN Huiqin. Research progresses on allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(3): 1-3. doi:10.6040/j.issn.1673-3770.1.2017.021. [2] Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases[J]. Expert Opin Ther Targets, 2018, 22(3): 263-277. doi:10.1080/14728222.2018.1439924. [3] Fritz G. RAGE: a single receptor fits multiple ligands[J]. Trends Biochem Sci, 2011, 36(12): 625-632. doi:10.1016/j.tibs.2011.08.008. [4] Ullah MA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation[J]. J Allergy Clin Immunol, 2014, 134(2): 440-450. doi:10.1016/j.jaci.2013.12.1035. [5] Huang WF, Zhao HJ, Dong HM, et al. High-mobility group box 1 impairs airway epithelial barrier function through the activation of the RAGE/ERK pathway[J]. Int J Mol Med, 2016, 37(5): 1189-1198. doi:10.3892/ijmm.2016.2537. [6] Zhu XW, Cong JN, Yang B, et al. Association analysis of high-mobility group box-1 protein 1(HMGB1)/toll-like receptor(TLR)4 with nasal interleukins in allergic rhinitis patients[J]. Cytokine, 2020, 126: 154880. doi:10.1016/j.cyto.2019.154880. [7] Yuan Y, Liu Q, Zhao J, et al. SIRT1 attenuates murine allergic rhinitis by downregulated HMGB 1/TLR4 pathway[J]. Scand J Immunol, 2018, 87(6): e12667. doi:10.1111/sji.12667. [8] Tang HP, Li TT, Han XL, et al. TLR4 antagonist ameliorates combined allergic rhinitis and asthma syndrome(CARAS)by reducing inflammatory monocytes infiltration in mice model[J]. Int Immunopharmacol, 2019, 73: 254-260. doi:10.1016/j.intimp.2019.05.021. [9] Shimizu S, Kouzaki H, Kato T, et al. HMGB1-TLR4 signaling contributes to the secretion of interleukin 6 and interleukin 8 by nasal epithelial cells[J]. Am J Rhinol Allergy, 2016, 30(3): 167-172. doi:10.2500/ajra.2016.30.4300. [10] Jiang Huanhuan, Duan Junyan, Xu Kaihong, et al. Resveratrol protects against asthma-induced airway inflammation and remodeling by inhibiting the HMGB1/TLR4/NF-κB pathway[J]. Experimental and therapeutic medicine vol, 2019,18(1): 459-466. doi: 10.3892/etm.2019.7594. [11] Zhang Han, Yang Nan, Wang Tianyue, et al. Vitamin D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NFκB signaling pathway[J].Molecular Medicine Reportsvol, 2018, 17(2): 2915-2920. doi: 10.3892/mmr.2017.8216. [12] 陈删. 高迁移率家族蛋白1在小鼠过敏性鼻炎及急性细菌性鼻窦炎中的表达及其意义[D]. 武汉: 华中科技大学, 2016. CHEN Shan. The role of high mobility group box 1 protein in murine allergic rhinitis and acute bacterial rhinosinusitis[D]. Wuhan: Huazhong University of Science and Technology, 2016. [13] Liang Y, Hou CC, Kong JL, et al. HMGB1 binding to receptor for advanced glycation end products enhances inflammatory responses of human bronchial epithelial cells by activating p38 MAPK and ERK1/2[J]. Mol Cell Biochem, 2015, 405(1/2): 63-71. doi:10.1007/s11010-015-2396-0. [14] 徐韶飞, 聂晚频, 姚凯, 等. HMGB1促进血管平滑肌细胞增殖与迁移的机制研究[J]. 中国普通外科杂志, 2015, 24(12): 1703-1708. doi: 10.3978/j.issn.1005-6947.2015.12.013. XU Shaofei, NIE Wanpin, YAO Kai, et al. Mechanism for HMGB1 in promoting migration and proliferation of vascular smooth muscle cells[J]. Chinese Journal of General Surgery, 2015, 24(12): 1703-1708. doi: 10.3978/j.issn.1005-6947.2015.12.013. [15] 吴欣阳, 朱宏岩, 吴革平. PI3K/PKB通道在肥大细胞介导的过敏性鼻炎中的多重作用[J]. 临床医药文献电子杂志, 2017, 4(72): 14255-14256. doi:10.16281/j.cnki.jocml.2017.72.163. [16] Zhang YL, You B, Liu XZ, et al. High-mobility group box 1(HMGB1)induces migration of endothelial progenitor cell via receptor for advanced glycation end-products(RAGE)-dependent PI3K/akt/Enos signaling pathway[J]. Med Sci Monit, 2019, 25: 6462-6473. doi:10.12659/MSM.915829. [17] Lee CC, Lai YT, Chang HT, et al. Inhibition of high-mobility group box 1 in lung reduced airway inflammation and remodeling in a mouse model of chronic asthma[J]. Biochem Pharmacol, 2013, 86(7): 940-949. doi:10.1016/j.bcp.2013.08.003. [18] Chen YC, Statt S, Wu RE, et al. High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells[J]. Sci Rep, 2016, 6: 18815. doi:10.1038/srep18815. [19] Kim TH, Lee JY, Lee HM, et al. Remodelling of nasal mucosa in mild and severe persistent allergic rhinitis with special reference to the distribution of collagen, proteoglycans, and lymphatic Vessels[J]. Clin Exp Allergy, 2010, 40(12): 1742-54. doi: 10.1111/j.1365-2222.2010.03612.x. [20] Cavone L, Cuppari C, Manti S, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophil cell death[J]. Clin Exp Otorhinolaryngol, 2015, 8(2): 123-128. doi:10.3342/ceo.2015.8.2.123. [21] 刘阳, 王志斌, 刘争, 等. 高迁移率族蛋白B1在变应性鼻炎中的表达及意义[J]. 中国免疫学杂志, 2010, 26(7): 651-654. LIU Yang, WANG Zhibin, LIU Zheng, et al. doi: CNKI:SUN:ZMXZ.0.2010-07-018. The expression of HMGB1 in nasal mucosa of allergic rhinitis patients and its significance[J]. Chinese Journal of Immunology, 2010, 26(7): 651-654. doi: CNKI:SUN:ZMXZ.0.2010-07-018. [22] Lu B, Wang C, Wang M, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review[J]. Expert Rev Clin Immunol, 2014, 10(6): 713-727. doi:10.1586/1744666X.2014.909730. [23] Pellegrini L, Xue JM, Larson D, et al. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma[J]. Oncotarget, 2017, 8(14): 22649-22661. doi:10.18632/oncotarget.15152. [24] Seo MS, Kim HJ, Kim H, et al. Ethyl pyruvate directly attenuates active secretion of HMGB1 in proximal tubular cells via induction of heme oxygenase-1[J]. J Clin Med, 2019, 8(5): E629. doi:10.3390/jcm8050629. [25] Liu YY, Chen NH, Chang CH, et al. Ethyl pyruvate attenuates ventilation-induced diaphragm dysfunction through high-mobility group box-1 in a murine endotoxaemia model[J]. J Cell Mol Med, 2019, 23(8): 5679-5691. doi:10.1111/jcmm.14478. [26] Wagner N, Dieteren S, Franz N, et al. Ethyl pyruvate ameliorates hepatic injury following blunt chest trauma and hemorrhagic shock by reducing local inflammation, NF-kappaB activation and HMGB1 release[J]. PLoS One, 2018, 13(2): e0192171. doi:10.1371/journal.pone.0192171. [27] Chen S, Wang YJ, Gong GQ, et al. Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release[J]. Exp Biol Med(Maywood), 2015, 240(11): 1490-1499. doi:10.1177/1535370214566563. [28] Bhat SM, Massey N, Karriker LA, et al. Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling[J]. Respir Res, 2019, 20(1): 27. doi:10.1186/s12931-019-0992-3. [29] Shin JH, Kim ID, Kim SW, et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium[J]. Mol Med, 2015, 20: 649-657. doi:10.2119/molmed.2014.00039. [30] Chen D, Bellussi LM, Cocca S, et al. Glycyrrhetinic acid suppressed hmgb1 release by up-regulation of Sirt6 in nasal inflammation[J]. J Biol Regul Homeost Agents, 2017, 31(2): 269-277. [31] Bellussi LM, Cocca S, Passali GC, et al. HMGB1 in the pathogenesis of nasal inflammatory diseases and its inhibition as new therapeutic approach: a review from the literature[J]. Int Arch Otorhinolaryngol, 2017, 21(4): 390-398. doi:10.1055/s-0036-1597665. |
| [1] | XIN Min, WANG Shaoming. Neuroimmune mechanisms and therapeutic strategies of inflammatory and infectious olfactory dysfunction [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(2): 111-124. |
| [2] | LYU Qian, TANG Yuan, GU Zijun, SHI Sailei, LIU Ping, WAN Wenjin. Current status of benefit finding among patients with allergic rhinitis and its influence factors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 21-28. |
| [3] | GU Min, LU Meiping. Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 106-111. |
| [4] | LIU Yijie, LU Xiuzhen, WU Qiuxin. Research rogress of exosomes in the pathogenesis, diagnosis and treatment in ophthalmic diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 135-141. |
| [5] | TANG Xi, HUANG Maoling, ZHANG Jiqiang, ZHONG Cheng. Correlation between aromatase and estrogen receptor expression in the primary auditory cortex of mice at different developmental stages and hearing ability [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 46-53. |
| [6] | QIN Nana, LI Yufen, SUN Yuhao, WEI Jian, LI Qin. Effect of interleukin-13 receptor-α2 on nasal mucosal remodeling in rats with allergic rhinitis by TGF-β1/Smad signaling pathway [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 71-77. |
| [7] | DU Kangli, ZHENG Zhenyu, XU Zhanjiang, ZHANG Yu, CHEN Lu, LU Mengyao. Construction and validation of risk prediction model for nasal septal deviation complicated with chronic sinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 78-86. |
| [8] | XIONG Qin, ZHANG Yan, WU Rina, LI Feng, TANG Lixing. Application of intranasal corticosteroids in pediatrics [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 160-167. |
| [9] | XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33. |
| [10] | HUANG Huan, HUA Hongli, DENG Yuqin, JIANG Chengyang, WANG Yuwei, YANG Xinghai. Correlation of allergic rhinitis, tonsil adenoid hypertrophy, and sinusitis in children and analysis of its clinical guiding value [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 34-41. |
| [11] | LIU Yijun, GU Yue, GUAN Dayu, YANG Yucheng, SHEN Yang. The long-term clinical efficacy and safety of vidian neurectomy in refractory allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 42-48. |
| [12] | ZHANG Ting, WANG Meilan, GAO Yingqin. Research progress of IL-35 in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 139-147. |
| [13] | LI Lilin, LI Xinyi, GUAN Jian. Research progress on the mechanism of comorbidity between obstructive sleep apnea and depression [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 89-96. |
| [14] | ZHANG Zhuping, PENG Zican, XIAO Zhenlong, LI Cheng, YU Di, WANG Xinglong, CHEN Wei, Guo Bei. The value of a novel nasal secretion eosinophil cationic protein-myeloperoxidase test paper assay in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 129-134. |
| [15] | LIU Chang, YANG Jingpu, GAO Yu, WANG Wenjia. Analysis of allergen detection results in children with allergic rhinitis in the Changchun area [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 51-58. |
|
||